Tolerion, Inc.

A vaccine that can prevent the damage to pancreatic β-cells in patients with type I diabetes has long been the Holy Grail of diabetes research. That goal has now come a step closer with the publicatio

It is now almost 20 years since the first patient was enrolled into an officially sanctioned gene therapy study, and in that time the field has been through a series of successes and setbacks. Today,

Versartis (US), an emerging biotechnology company developing therapeutics for metabolic diseases and endocrine disorders, has appointed Paul Westberg senior vice-president of business development. He

Genentech is to pay the US private biopharmaceutical company Bayhill Therapeutics $25 million up-front and potential milestones of more than $325 million to develop and commercialise BHT-3021, a DNA-b